Merck
CN
  • Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.

Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.

Digestive diseases and sciences (2014-09-23)
Javier P Gisbert, Jesús Barrio, Inés Modolell, Javier Molina-Infante, Angeles Perez Aisa, Manuel Castro-Fernández, Luis Rodrigo, Angel Cosme, Jose Luis Gisbert, Miguel Fernández-Bermejo, Santiago Marcos, Alicia C Marín, Adrián G McNicholl
摘要

Helicobacter pylori eradication is a challenge in penicillin allergy. To assess the efficacy and safety of first-line and rescue treatments in patients allergic to penicillin. Prospective multicenter study. Patients allergic to penicillin were given a first-line treatment comprising (a) 7-day omeprazole-clarithromycin-metronidazole and (b) 10-day omeprazole-bismuth-tetracycline-metronidazole. Rescue treatments were as follows: (a) bismuth quadruple therapy; (b) 10-day PPI-clarithromycin-levofloxacin; and (c) 10-day PPI-clarithromycin-rifabutin. Eradication was confirmed by (13)C-urea breath test. Compliance was determined through questioning and recovery of empty medication envelopes. Adverse effects were evaluated by questionnaires. In total, 267 consecutive treatments were included. (1) First-line treatment: Per-protocol and intention-to-treat eradication rates with omeprazole-clarithromycin-metronidazole were 59 % (62/105; 95 % CI 49-62 %) and 57 % (64/112; 95 % CI 47-67 %). Respective figures for PPI-bismuth-tetracycline-metronidazole were 75 % (37/49; 95 % CI 62-89 %) and 74 % (37/50; 95 % CI (61-87 %) (p < 0.05). Compliance with treatment was 94 and 98 %, respectively. Adverse events were reported in 14 % with both regimens (all mild). (2) Second-line treatment: Intention-to-treat eradication rate with omeprazole-clarithromycin-levofloxacin was 64 % both after triple and quadruple failure; compliance was 88-100 %, with 23-29 % adverse effects (all mild). (3) Third-/fourth-line treatment: Intention-to-treat eradication rate with PPI-clarithromycin-rifabutin was 22 %. In allergic to penicillin patients, a first-line treatment with a bismuth-containing quadruple therapy (PPI-bismuth-tetracycline-metronidazole) seems to be a better option than the triple PPI-clarithromycin-metronidazole regimen. A levofloxacin-based regimen (together with a PPI and clarithromycin) represents a second-line rescue option in the presence of penicillin allergy.

材料
货号
品牌
产品描述

Supelco
奥美拉唑, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
甲硝唑, analytical standard
Supelco
甲硝唑, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Levofloxacin, 98.0-102.0% anhydrous basis (HPLC)
Sigma-Aldrich
甲硝唑, BioXtra
Sigma-Aldrich
奥美拉唑, solid
Sigma-Aldrich
铋, powder, −100 mesh, 99% trace metals basis
Sigma-Aldrich
铋, powder, −100 mesh, ≥99.99% trace metals basis
USP
奥美拉唑, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
铋, pieces, 1-12 mm, 99.999% trace metals basis
Supelco
Levofloxacin, analytical standard
Supelco
奥美拉唑, analytical standard
Supelco
甲硝唑, VETRANAL®, analytical standard
奥美拉唑, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
铋, shot, 4-30 mesh, 99.9% trace metals basis
甲硝唑, European Pharmacopoeia (EP) Reference Standard
奥美拉唑, European Pharmacopoeia (EP) Reference Standard
铋, foil, 25x25mm, thickness 0.25mm, 100%
Sigma-Aldrich
铋, beads, 1-5 mm, 99.999% trace metals basis
铋, foil, 50x50mm, thickness 0.25mm, 100%
铋, foil, light tested, 50x50mm, thickness 0.02mm, permanent polyester support, 99.97%
铋, foil, 25x25mm, thickness 2.0mm, 100%
铋, foil, 50x50mm, thickness 2.0mm, 100%
铋, foil, 50x50mm, thickness 1.0mm, 100%
铋, foil, 25x25mm, thickness 1.0mm, 100%
铋, foil, 50x50mm, thickness 0.5mm, 100%
铋, foil, 25x25mm, thickness 0.5mm, 100%
铋, foil, light tested, 25x25mm, thickness 0.02mm, permanent polyester support, 99.97%
铋, foil, not light tested, 150x150mm, thickness 0.025mm, permanent polyester support, 99.97%
铋, foil, light tested, 50x50mm, thickness 0.015mm, permanent polyester support, 99.97%